NZ583351A - Modulate smooth muscle myosin and/or non-muscle myosin - Google Patents

Modulate smooth muscle myosin and/or non-muscle myosin

Info

Publication number
NZ583351A
NZ583351A NZ583351A NZ58335108A NZ583351A NZ 583351 A NZ583351 A NZ 583351A NZ 583351 A NZ583351 A NZ 583351A NZ 58335108 A NZ58335108 A NZ 58335108A NZ 583351 A NZ583351 A NZ 583351A
Authority
NZ
New Zealand
Prior art keywords
muscle myosin
methyl
formula
disease
isoquinolyl
Prior art date
Application number
NZ583351A
Other languages
English (en)
Inventor
David Morgans
Xiangping Qian
Chihyuan Grace Chuang
Pu-Ping Lu
Bing Yao
Qing Kevin Lu
Hong Jiang
Wenyue Wang
Bradley P Morgan
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ583351(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of NZ583351A publication Critical patent/NZ583351A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NZ583351A 2007-08-15 2008-08-11 Modulate smooth muscle myosin and/or non-muscle myosin NZ583351A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96502007P 2007-08-15 2007-08-15
PCT/US2008/009636 WO2009023193A1 (en) 2007-08-15 2008-08-11 Certain chemical entities, compositions, and methods

Publications (1)

Publication Number Publication Date
NZ583351A true NZ583351A (en) 2012-05-25

Family

ID=40350992

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583351A NZ583351A (en) 2007-08-15 2008-08-11 Modulate smooth muscle myosin and/or non-muscle myosin

Country Status (14)

Country Link
US (3) US8088793B2 (cg-RX-API-DMAC7.html)
EP (1) EP2195328A4 (cg-RX-API-DMAC7.html)
JP (1) JP5670731B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100044251A (cg-RX-API-DMAC7.html)
CN (1) CN101821279A (cg-RX-API-DMAC7.html)
AR (1) AR069364A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008287435B2 (cg-RX-API-DMAC7.html)
CA (1) CA2696321A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002411A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001692A (cg-RX-API-DMAC7.html)
NZ (1) NZ583351A (cg-RX-API-DMAC7.html)
PE (1) PE20090958A1 (cg-RX-API-DMAC7.html)
TW (1) TWI426908B (cg-RX-API-DMAC7.html)
WO (1) WO2009023193A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071625B2 (en) * 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2009023193A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
PH12013501489A1 (en) * 2010-12-17 2013-08-28 Hoffmann La Roche Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
SG10201701101YA (en) * 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
US9440919B2 (en) 2012-07-19 2016-09-13 Cayman Chemical Company, Inc. Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
WO2014144500A2 (en) * 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN110709392B (zh) 2017-03-30 2023-09-29 豪夫迈·罗氏有限公司 作为hpk1抑制剂的异喹啉
AU2018244935A1 (en) 2017-03-30 2019-08-15 F. Hoffmann-La Roche Ag Naphthyridines as inhibitors of HPK1
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
EP3826721B1 (en) 2018-07-24 2023-10-11 F. Hoffmann-La Roche AG Naphthyridine compounds and uses thereof
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227709A (en) * 1961-11-28 1966-01-04 Merck & Co Inc Derivatives of cephalosporin c and process
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
DE2851953A1 (de) * 1978-12-01 1980-06-19 Thomae Gmbh Dr K Neue spectinomycylamine, verfahren zu ihrer herstellung und diese enthaltenden arzneimittel
JP2838148B2 (ja) * 1991-08-15 1998-12-16 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
JPH07247274A (ja) * 1994-03-10 1995-09-26 Wakamoto Pharmaceut Co Ltd ピバル酸 テトラゾリルフェニルエステル誘導体、それらを有効成分として含有するエラスターゼ阻害剤及び肺障害治療剤
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
WO1998041510A1 (en) 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Novel benzolactam derivatives and medicinal compositions comprising the same
TR200001399T2 (tr) 1997-11-18 2000-11-21 Teijin Limited Siklik amin türevleri ve ilaç olarak kullanımları.
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
GB9807833D0 (en) * 1998-04-09 1998-06-10 Boc Group Plc Separation of air
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
CA2321348A1 (en) 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
CA2462903C (en) 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
AR038368A1 (es) * 2002-02-01 2005-01-12 Novartis Ag Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
US7294642B2 (en) * 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
EP1615878B1 (en) 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20060178403A1 (en) * 2003-03-07 2006-08-10 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
WO2005016883A2 (en) * 2003-08-14 2005-02-24 Icos Corporation Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
JP4380508B2 (ja) * 2003-11-28 2009-12-09 田辺三菱製薬株式会社 医薬組成物
AU2005210594A1 (en) * 2004-02-04 2005-08-18 Active Biotech Ab Diurea derivatives
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
WO2006137350A1 (ja) 2005-06-22 2006-12-28 Kissei Pharmaceutical Co., Ltd. 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2009514866A (ja) * 2005-11-02 2009-04-09 サイトキネティクス・インコーポレーテッド ある種の化学物質、組成物、および方法
WO2007109615A2 (en) * 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2007143822A1 (en) * 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
WO2008016676A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US8071625B2 (en) 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8063082B2 (en) 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2009023193A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods

Also Published As

Publication number Publication date
US8088793B2 (en) 2012-01-03
PE20090958A1 (es) 2009-08-07
US8759374B2 (en) 2014-06-24
TW200922583A (en) 2009-06-01
KR20100044251A (ko) 2010-04-29
JP2010536752A (ja) 2010-12-02
US20120135964A1 (en) 2012-05-31
US20090275537A1 (en) 2009-11-05
AU2008287435B2 (en) 2013-05-16
US20130053348A1 (en) 2013-02-28
WO2009023193A1 (en) 2009-02-19
EP2195328A4 (en) 2011-06-15
CA2696321A1 (en) 2009-02-19
TWI426908B (zh) 2014-02-21
EP2195328A1 (en) 2010-06-16
US8895582B2 (en) 2014-11-25
CL2008002411A1 (es) 2009-07-17
AR069364A1 (es) 2010-01-20
AU2008287435A1 (en) 2009-02-19
MX2010001692A (es) 2010-04-22
CN101821279A (zh) 2010-09-01
JP5670731B2 (ja) 2015-02-18

Similar Documents

Publication Publication Date Title
NZ583351A (en) Modulate smooth muscle myosin and/or non-muscle myosin
RU2494095C2 (ru) Модифицированные миметики лизина
TN2009000253A1 (en) Solid dispersion of a neurokinin antagonist
NZ591024A (en) Substituted pyrrolidine-2-carboxamides
WO2009049180A3 (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
WO2010005958A3 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
MX2009004289A (es) Compuestos triciclicos como inhibidores de metaloproteinasas matriciales.
NZ596922A (en) Thiophene analogues for the treatment or prevention of Flavivirus infections
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
MY142453A (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
EA200870471A1 (ru) Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
PL2049475T3 (pl) Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
PL2021337T3 (pl) Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
EA016687B8 (ru) Производные циклопропиламида
CN102036956A (zh) 取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法
WO2008008718B1 (en) Cyclopentane derivatives as antiglaucoma agents
EA200800081A1 (ru) Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
MY151072A (en) Heteroaryl derivative
US20090012011A1 (en) Novel Compounds
WO2006002434A3 (en) Novel indazole carboxamides and their use

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF DISCLAIMER

ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: MODULATORS OF SMOOTH MUSCLE AND NON-MUSCLE MYOSIN; FILING DATE: 17 FEB 2010; STATUS: REJECTED; TITLE: MODULATORS OF SMOOTH MUSCLE AND NON-MUSCLE MYOSIN; FILING DATE: 30 APR 2012; STATUS: OVERWRITTEN; TITLE: MODULATORS OF SMOOTH MUSCLE AND NON-MUSCLE MYOSIN; FILING DATE: 15 NOV 2010; STATUS: REJECTED; TITLE: MODULATORS OF SMOOTH MUSCLE AND NON-MUSCLE MYOSIN; FILING DATE: 18 OCT 2011; STATUS: REJECTED; TITLE: MODULATORS OF SMOOTH MUSCLE AND NON-MUSCLE MYOSIN; FILING DATE: 23 MAR 2012; STATUS: REJECTED; TITLE: MODULATORS OF SMOOTH MUSCLE AND NON-MUSCLE MYOSIN; FILING DATE: 25 MAY 2012; STATUS: SUPERSEDED; PUBLICATION DATE: 25 MAY 2012; TITLE: MODULATORS OF

Effective date: 20130307

LAPS Patent lapsed